-
The competing risk approach for prediction of preeclampsia.
Wright D, Wright A, Nicolaides KH.
Am J Obstet Gynecol 2020;223:12-23.e7. pdf -
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:400-407. pdf -
Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study.
Poon LC, Wright D, Thornton S, Akolekar R, Brocklehurst P, Nicolaides KH.
Southampton (UK): NIHR Journals Library 2020 pdf -
Impact of new definitions of pre-eclampsia on incidence and performance of first-trimester screening.
Khan N, Andrade W, De Castro H, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;55:50-57. pdf -
Proposed clinical management of pregnancies after combined screening for preeclampsia at 35-37 weeks' gestation.
Panaitescu AM, Wright D, Militello A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017:50:383-387. pdf -
Proposed clinical management of pregnancies after combined screening for preeclampsia at 19-24 weeks' gestation.
Litwinska M, Wright D, Efeturk T, Ceccacci I, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:367-372. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
The duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction.
Turan OM, Turan S, Berg C, Gembruch U, Nicolaides KH, Harman CR, Baschat AA.
Ultrasound Obstet Gynecol 2011;38:295-302. -
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011;31:58-65. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75.